The MHRA relaxed its interpretation of GMP which means UK Biopharma firms have a reduced testing burden during the Covid-19 pandemic. The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) announced the move last week, explaining the aim was to let drug firms focus quality system capacity on ensuring supply continuity. Under the plan, firms importing ingredients and finished products will only be required to test to confirm their identity. For other quality attributes importers are permitted to use…